Signal Transduction
Stem Cells
Signaling Pathways
Product Type
All Products
New Products
Small Molecules
Peptides
Controlled Substances
Toxins
Caged Compounds
Fluorescent Probes
Screening Libraries
Ligand Sets
Other Product Types
Research Area
Cancer
Cardiovascular System
Endocrinology
Immunology
Neuroscience
Pain & Inflammation
Respiratory System
SR 27897Cat. No. 2190 |
Price and AvailabilityBy clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy. |
|
Alternative Name: Lintitript Chemical Name: 2-[[[4-(2-Chlorophenyl)-2-thiazolyl]amino]carbonyl]-1H-indole-1-acetic acid |
Biological Activity
Potent, non-peptide CCK1 receptor antagonist that displays > 33-fold selectivity over CCK2 receptors (EC50 values are 6 and 200 nM respectively). Causes an increase in plasma leptin levels and increases food intake in rats in vivo.Certificate of Analysis / Safety Data Sheet
References
Gully et al (1993) Peripheral biological activity of SR 27897: a new potent non-peptide antagonist of CCKA receptors. Eur.J.Pharmacol. 23 232.
Gouldson et al (1999) Contrasting roles of Leu356 in the human CCK1 receptor for antagonist SR 27897 and agonist SR 146131 binding. Eur.J.Pharmacol. 383 339. PMID: 10594328.
Cano et al (2003) Regulation of leptin distribution between plasma and cerebrospinal fluid by cholecystokinin receptors. Br.J.Pharmacol. 140 647. PMID: 14534148.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: SR 27897, supplier, Potent, selective, CCK1, antagonists, Cholecystokinin1, Receptors, CCK, Cholecystokinin, SR27897
Quick Order
Find multiple products by catalog number
Appetite Modulation
Written by Sonia A. Tucci, Lynsay Kobelis & Tim Kirkham. Request a copy or view PDF today.
Gut Hormones and the Regulation of Appetite
Written by V.J. Taylor et al
'Gut Hormones and the Regulation of Appetite' summarizes the neuropeptide modulators and gut hormones that influence appetite
7-TM Receptor Signaling
Written by T. Kenakin et al
'Seven Transmembrane Receptor Signaling' highlights the multiple behaviors of 7-TMs including G-protein-dependent and -independent signaling as well as the concept of collateral efficacy
20% Discount*
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.